Omnicell Inc. Stock
Price
Target price
€32.60
€32.60
-16.410%
-6.4
-16.410%
€37.07
06.02.26 / Frankfurt
WKN: 632313 / Symbol: OMCL / Name: Omnicell / Stock / Healthcare Equipment & Supplies / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Omnicell Inc. Stock
Omnicell Inc. took a tumble today and lost -€6.400 (-16.410%).
Omnicell Inc. is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
As a result the target price of 37 € shows a slightly positive potential of 13.5% compared to the current price of 32.6 € for Omnicell Inc..
Pros and Cons of Omnicell Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Cons
?
C******** o* t** e**********
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Omnicell Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Omnicell Inc. | -16.410% | -20.098% | -18.500% | -23.113% | -15.979% | -37.905% | -68.952% |
| Healthequity Inc. | 0.000% | -7.639% | -18.405% | -37.850% | -14.744% | 20.909% | -5.674% |
| Bruker Corp. | 2.440% | -5.032% | -21.278% | -34.199% | -13.018% | - | - |
| Myriad Genetics | -0.470% | -8.936% | -22.883% | -65.203% | -19.245% | -76.116% | -82.032% |
Comments
Omnicell (NASDAQ:OMCL) was upgraded by analysts at Bank of America Corporation from a "neutral" rating to a "buy" rating. They now have a $70.00 price target on the stock.
Show more
Ratings data for OMCL provided by MarketBeat
Omnicell (NASDAQ:OMCL) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Show more
Ratings data for OMCL provided by MarketBeat
Omnicell (NASDAQ:OMCL) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Show more
Ratings data for OMCL provided by MarketBeat
News
Omnicell Executive Trims Holdings in $244,000 Sale as Stock Trades Near 2025 Highs
Corey J Manley, EVP & Chief Legal/Admin Officer at Omnicell (NASDAQ:OMCL), executed an open-market sale of 6,106 shares for $243,629.40 on Dec. 3, 2025, as reported in the SEC Form 4 filing.
Why Omnicell Stock Crushed the Market Today
Healthcare tech company Omnicell (NASDAQ: OMCL) was quite the picture of health on Thursday, at least as far as its equity was concerned. An encouraging quarterly earnings report sent its shares